GlaxoSmithKline (GSK), one of the world’s leading research-based pharmaceutical and healthcare companies, has decided to close its medicine manufacturing unit in Bangladesh after over six decades of operation.
The GSK Bangladesh board of directors is proposing the closure following a business review and expecting to complete the process by the end of this year. The firm pledged ‘appropriate support’ to over 1,000 of its employees. The factory has around 500 officials and workers while 500 others are engaged in sales and marketing jobs across Bangladesh. GSK Bangladesh staffers at its pharmaceutical plant in Chattogram’s Faujdarhat demonstrated against the decision to close operations.
GSK Vaccines, which are purchased via the UN’s wing for children UNICEF and funded by Gavi, the Vaccine Alliance, will continue to be available in Bangladesh.
GSK Bangladesh Ltd would continue with its profitable consumer health care business that produces items like Horlicks, Sensodyne and Glaxose-D.